RxDoctor Payments Data

Alexandra Flanigan

Psychiatric/Mental Health · Beaver, PANPI 1568014215

Payments from drug & device makers

$3,248in general payments, 2019–2025

Across 71 payments — averaging $45.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$738
  • Acadia Pharmaceuticals Inc$679
  • Neurocrine Biosciences, Inc.$634
  • Teva Pharmaceuticals USA, Inc.$400
  • Avanir Pharmaceuticals, Inc.$316
  • Otsuka America Pharmaceutical, Inc.$184
  • plus $297 from 6 others

What the payments were for

  • Food & beverage$3,13797%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,248 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,399
Medicare patients
561
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$144,435
NuplazidPimavanserin Tartrate14$74,147
VraylarCariprazine Hcl62$66,557
Invega SustennaPaliperidone Palmitate11$40,907
TrintellixVortioxetine Hydrobromide34$10,957
Paliperidone ErPaliperidone41$5,505
Quetiapine Fumarate148$4,665
Sertraline Hcl263$4,563
Ramelteon25$3,058
Aripiprazole30$2,863
Olanzapine91$2,680
Trazodone Hcl155$2,631
Clozapine102$2,511
Fluoxetine Hcl53$2,414
Duloxetine Hcl46$2,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$634$144,43517 claims
Acadia Pharmaceuticals IncNuplazid$679$74,14714 claims
AbbVieVraylar$39$66,55762 claims
Johnson & JohnsonInvega Sustenna$12$40,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Beaver

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →